QR Pharma Begins Collaboration on Posiphen and Huntingtona s disease

The collaboration will focus on preclinical research involving QR's lead drug candidate, Posiphen A . Investigators at Rockefeller will conduct experiments in stem cell culture models of HD to determine, if Posiphen lowers the levels of the toxic huntingtin protein in these cells, if it promotes differentiation into neuronal cells and, if it prolongs the cell life of the HD cells.

http://ift.tt/1AspH0B